[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Kim JG, Sung WJ, Kim DH, Kim YH, Sohn SK, Lee KB: Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass. Korean J Intern Med; 2005 Mar;20(1):100-4
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass.
  • A malignant peripheral nerve sheath tumor (MPNST) is an extremely rare soft tissue tumor in the general population.
  • On the other hand, there is a higher incidence of MPNST in patients with neurofibromatosis type I (von Recklinghausen's disease).
  • The common sites are the extremities, trunk, head and neck.
  • This paper reports two patients, a 31 year-old woman with multiple neurofibromatosis presenting as an intraabdominal malignant peripheral nerve sheath tumor, and a 33 year-old woman with an intrathoracic malignant peripheral nerve sheath tumor.
  • The patients were treated with chemotherapy followed by radiotherapy.
  • However, one patient died as a result of disease progression 21 months after the diagnosis and the other patient is currently being treated with radiotherapy.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / complications. Thoracic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Peripheral type neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] J Neurosurg Sci. 1989 Jul-Sep;33(3):253-7 [2614511.001]
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):126-9 [6766081.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Jul 27;383(1):43-57 [157612.001]
  • [Cites] Cancer. 1977 May;39(5):1955-8 [858125.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):64-9 [12504660.001]
  • [Cites] Korean J Intern Med. 2001 Sep;16(3):201-4 [11769579.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Cancer. 1963 Aug;16:1015-27 [14050005.001]
  • [Cites] Scand Cardiovasc J. 1998;32(3):173-5 [9764434.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1996 Jun;44(6):864-8 [8753103.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • (PMID = 15906964.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891405
  •  go-up   go-down


2. Mondal PK, Pal I, Misra S, Biswas S, Bera SP: Rhabdomyosarcoma of nose, nasopharynx and paranasal sinuses. Indian J Otolaryngol Head Neck Surg; 2009 Dec;61(4):317-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma is an aggressive malignant soft tissue tumor that arises from primitive striated muscle cells called rhabdomyoblasts.
  • It is the most common soft tissue malignant tumor in children and accounts for about 7-8% of childhood cancers.
  • It can arise from almost anywhere in the body but it is most common in the head and neck region.
  • This article presents six cases of rhabdomyosarcoma involving the nose, nasopharynx and the paranasal sinuses four of which were treated with a combination of radiotherapy and chemotherapy and two were treated with medial maxillectomy combined with chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 Jan;37(1):364-76 [1247965.001]
  • [Cites] J Clin Invest. 1991 Apr;87(4):1133-8 [1849142.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • [Cites] Arch Surg. 1962 May;84:582-8 [13886586.001]
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):337-44 [10888419.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Sep;103(9):699-704 [8085730.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):26-38 [8202644.001]
  • (PMID = 23120658.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450072
  • [Keywords] NOTNLM ; Nasopharynx / Nose / Paranasal sinuses / Rhabdomyosarcoma
  •  go-up   go-down


3. McCarthy EF: The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J; 2006;26:154-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
  • He thought that the infection he produced would have the side effect of shrinking the malignant tumor.
  • Over the next forty years, as head of the Bone Tumor Service at Memorial Hospital in New York, Coley injected more than 1000 cancer patients with bacteria or bacterial products.
  • He and other doctors who used them reported excellent results, especially in bone and soft-tissue sarcomas.
  • This criticism, along with the development of radiation therapy and chemotherapy, caused Coley's Toxins to gradually disappear from use.
  • [MeSH-major] Sarcoma / therapy
  • [MeSH-minor] Bacterial Toxins / therapeutic use. History, 19th Century. Humans. Immunotherapy / history. Soft Tissue Neoplasms / therapy. United States

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Pharmacother. 2000 May;1(4):603-14 [11249505.001]
  • [Cites] Cancer Immunol Immunother. 2001 Oct;50(8):391-6 [11726133.001]
  • [Cites] Postgrad Med J. 2003 Dec;79(938):672-80 [14707241.001]
  • [Cites] Clin Orthop Relat Res. 1991 Jan;(262):3-11 [1984929.001]
  • [Cites] Cancer Chemother Rep. 1962 Aug;21:43-68 [14452138.001]
  • [Cites] Nature. 1992 May 7;357(6373):11-2 [1574121.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Iowa Orthop J. 1995;15:74-8 [7634048.001]
  • [Cites] Crit Rev Oncol Hematol. 1996 Apr;22(3):213-28 [8793276.001]
  • [Cites] Adv Exp Med Biol. 1990;267:483-500 [2088067.001]
  • (PMID = 16789469.001).
  • [ISSN] 1541-5457
  • [Journal-full-title] The Iowa orthopaedic journal
  • [ISO-abbreviation] Iowa Orthop J
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Toxins
  • [Personal-name-as-subject] Coley WB
  • [Other-IDs] NLM/ PMC1888599
  •  go-up   go-down


Advertisement
4. Shah JP, Gil Z: Current concepts in management of oral cancer--surgery. Oral Oncol; 2009 Apr-May;45(4-5):394-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the most well established mode of initial definitive treatment for a majority of oral cancers.
  • The factors that affect choice of treatment are related to the tumor and the patient.
  • The radial forearm free flap provides excellent soft tissue and lining for soft tissue defects in the oral cavity.
  • Over the course of the past thirty years there has been improvement in the overall survival of patients with oral carcinoma largely due to the improved understanding of the biology of local progression, early identification and treatment of metastatic lymph nodes in the neck, and employment of adjuvant post-operative radiotherapy or chemoradiotherapy.
  • The role of surgery in primary squamous cell carcinomas in other sites in the head and neck has evolved with integration of multidisciplinary treatment approaches employing chemotherapy and radiotherapy either sequentially or concurrently.
  • Advances in skull base surgery have significantly improved the survivorship of patients with malignant tumors of the paranasal sinuses approaching or involving the skull base.
  • Surgery thus remains the mainstay of management of a majority of neoplasms arising in the head and neck area.
  • Similarly, the role of the surgeon is essential throughout the life history of a patient with a malignant neoplasm in the head and neck area, from initial diagnosis through definitive treatment, post-treatment surveillance, management of complications, rehabilitation of the sequelae of treatment, and finally for palliation of symptoms.
  • [MeSH-minor] Antineoplastic Protocols. Bone Neoplasms / surgery. Combined Modality Therapy. Head and Neck Neoplasms / surgery. Humans. Patient Selection. Reconstructive Surgical Procedures. Skin Neoplasms / surgery. Skull Base Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps. Treatment Outcome


5. Sanders KW, Fowler MR, Milner J, Stucker FJ, Nathan CO: Aggressive fibromatosis of the parapharyngeal space: two cases and treatment recommendations. Ear Nose Throat J; 2004 Apr;83(4):262, 264, 266 passim
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive fibromatosis of the parapharyngeal space: two cases and treatment recommendations.
  • Aggressive fibromatosis is an uncommon tumor that is locally aggressive but not malignant.
  • Therefore, its classification falls between the benign and malignant neoplasms of soft-tissue origin.
  • Otolaryngologists should be familiar with these lesions because as many as 15% of them occur in the head and neck.
  • The treatment of choice is wide surgical excision, which is often difficult.
  • Nonsurgical treatment includes radiation and chemotherapy, both of which are usually reserved for recurrences.
  • We describe two cases of aggressive fibromatosis of the parapharyngeal space, and we review the available treatment options.
  • [MeSH-major] Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / therapy. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / therapy. Pharynx / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Connective Tissue / pathology. Diagnosis, Differential. Female. Humans. Male. Otorhinolaryngologic Surgical Procedures. Recurrence


6. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


7. Sturgis EM, Potter BO: Sarcomas of the head and neck region. Curr Opin Oncol; 2003 May;15(3):239-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the head and neck region.
  • PURPOSE OF REVIEW: This review discusses the classification, etiology, diagnosis, evaluation, treatment, and prognosis of sarcoma of the head and neck region.
  • RECENT FINDINGS: Sarcomas account for less than 1% of all malignancies in the United States with only 5 to 15% of these sarcomas occurring in the head and neck region.
  • However, about 1 in 3 pediatric sarcomas will occur in the head and neck region.
  • Pathologic classification is critical to the ultimate treatment and prognosis of sarcoma of the head and neck.
  • Osteosarcoma, rhabdomyosarcoma, malignant fibrous histiocytoma, and angiosarcoma are the most common types of sarcoma to occur in the head and neck region; however, up to 20% of head and neck sarcomas will remain unclassified.
  • Adjuvant chemotherapy is being utilized and/or studied for most high-grade sarcomas and adjuvant radiotherapy is important for disease control in high-grade soft-tissue sarcomas.
  • Prognosis is clearly related to tumor grade and margin status.
  • SUMMARY: Sarcomas of the head and neck region are rare malignancies often without a clear etiology.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Hemangiosarcoma / mortality. Hemangiosarcoma / pathology. Hemangiosarcoma / therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteosarcoma / mortality. Osteosarcoma / pathology. Osteosarcoma / therapy. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Risk Assessment. Surgical Procedures, Operative / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778019.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 157
  •  go-up   go-down


8. Rodrigues TA, Quintela AG, Luz RM, López D: [Thyroid carcinoma with thymus-like differentiation (CASTLE): case report and review of the literature]. Arq Bras Endocrinol Metabol; 2008 Apr;52(3):550-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinoma da tireóide com diferenciação semelhante a timo (CASTLE): relato de caso e revisão da literatura.
  • Carcinoma with thymus-like differentiation (CASTLE) is a rare malignant epithelial tumor which arises on soft tissue of the neck or thyroid gland.
  • It is important to differentiate CASTLE from primary or metastatic squamous cell carcinoma of head and neck, and from squamous cell thyroid carcinoma, because it has a different prognosis.
  • CD5 immunoreactivity might be helpful in CASTLE diagnosis.
  • Treatment includes surgical excision and radiotherapy.
  • Chemotherapy can be offered, although its efficacy is not clear.
  • After radiotherapy and chemotherapy, minimal response was obtained.
  • The authors intend to discuss the differential pathologic diagnosis and the best therapy of this indolent but recurrent neoplasm, that demands strict long term follow-up.
  • [MeSH-major] Carcinoma / pathology. Head and Neck Neoplasms / pathology. Thymus Gland / pathology. Thymus Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Soft Tissue Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506281.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 20
  •  go-up   go-down


9. Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM: Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol; 2001 Jun;25(6):699-709
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor.
  • Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon tumor of deep soft tissues, originally described in 1995 by Meis-Kindblom et al.
  • The group consisted of six male and 10 female patients (age range, 14-55 years; mean age, 40 years), and the tumors were located in a limb or limb girdle (n = 7), base of the penis (n = 1), back or chest wall (n = 3), and head and neck (n = 5).
  • Tumor size ranged from 3.7 to 22 cm (mean, 8.9 cm).
  • The only consistent immunohistochemical finding was a strong, diffuse reactivity of tumor cells for vimentin.
  • Bone invasion and tumor necrosis, features not reported before, were found in six cases each.
  • Treatment consisted of intralesional excision (n = 2), attempted wide local excision (n = 11), and amputation (n = 3), with either adjuvant radiation therapy (n = 9) or chemotherapy (n = 3).
  • Eight patients (57%) died of disease 16 to 86 months after diagnosis.
  • SEF shares some pathologic features with two other fibrosing fibrosarcomas, low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes, but in the authors' experience behaves clinically as a fully malignant sarcoma.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. el-Zeftawy H, Heiba SI, Jana S, Rosen G, Salem S, Santiago JF, Abdel-Dayem HM: Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother Radiopharm; 2001 Feb;16(1):37-46
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
  • AIM OF THE STUDY: To assess the impact of repeated F-18 FDG studies on the management of patients with bone and soft tissue (B&S) sarcomas.
  • MATERIAL AND METHODS: Twenty patients with B&S tissue tumors (11 M and 9 F age 17-72 years) had 52 F-18 FDG Dual Head Coincidence Imaging (DHCI) studies.
  • 7 patients were followed for 6 months to 2 years clinically after removal of the primary tumor.
  • Patient's preparation, F-18 FDG injection and imaging procedure were done according to department protocol.
  • Tumor to background ratios were calculated for all lesions.
  • Follow up studies showed stable disease in 10 patients while 6 patients who showed worsening disease needed to change their chemotherapy.
  • CONCLUSION: Repeated F-18 FDG DHCI examinations proved to have an impact on the clinical management of patients with malignant bone and soft tissue sarcoma.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Sarcoma / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Gland Neoplasms / secondary. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Male. Middle Aged. Posture. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11279796.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Yu H, Wang CF, Yang WT, Zhu XZ: [Angiomatoid fibrous histiocytoma: report of 5 cases with review of literature]. Zhonghua Bing Li Xue Za Zhi; 2010 Apr;39(4):245-8
Genetic Alliance. consumer health - Histiocytoma, angiomatoid fibrous.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of angiomatoid fibrous histiocytoma (AFH).
  • The mass was located in the head and neck region in 3 cases, elbow in 1 case and foot in 1 case.
  • The patients underwent complete resection of the tumor, with no adjuvant chemotherapy and/or radiotherapy given.
  • Gross examination showed that the tumor was well-circumscribed and had a grey-colored cut surface, with focal hemorrhagic cystic changes.
  • The average tumor dimension was 1.9 cm.
  • Histologically, the tumor was composed of histiocytoid or spindly cells arranged in nodular pattern.
  • Fibrillary neuropil-type intercellular material was identified in all cases and a fibrous pseudocapsule surrounded by lymphocytes and plasma cells was demonstrated in 3 cases.
  • CONCLUSIONS: AFH is a rare tumor of intermediate malignant potential.
  • Definitive diagnosis requires thorough histologic examination and clinical correlation.
  • Immunohistochemistry is also helpful for diagnosis and differential diagnosis.
  • Wide local excision with post-operative follow up is the main modality of treatment.
  • [MeSH-major] Histiocytoma, Benign Fibrous / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aneurysm / metabolism. Aneurysm / pathology. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Chemotherapy, Adjuvant. Child. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / pathology. Humans. Male. Radiotherapy, Adjuvant. Vimentin / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654123.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Desmin; 0 / Vimentin
  •  go-up   go-down


12. Bisogno G, De Rossi C, Gamboa Y, Sotti G, Ferrari A, Dallorso S, Donfrancesco A, Cecchetto G, Calderone M, Gandola L, Rosolen A, Carli M: Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Jun;50(6):1154-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee.
  • BACKGROUND: Parameningeal rhabdomyosarcoma (PM-RMS) is a rare, highly malignant pediatric tumor arising from locations adjacent to the meninges, from where it can spread intracranially.
  • PROCEDURE: We reviewed 109 children with non-metastatic PM-RMS enrolled in the Italian RMS79, RMS88 and RMS96 protocols over a 24-year period.
  • All patients received intensive chemotherapy and standard or hyperfractionated and accelerated radiotherapy.
  • RESULTS: Five-year overall survival rose from 40% in the RMS79 to 72% in the RMS88 and RMS96 protocols (P = 0.01), where more intensive chemotherapy and hyperfractionated accelerated radiotherapy (HART) was used.
  • Delayed surgery after initial treatment was statistically associated with a better prognosis.
  • Unfavorable tumor characteristics for RMS arising in other sites, for example, histology, invasiveness or node involvement, did not predict outcome for PM-RMS.
  • CONCLUSION: Outcome in PM-RMS patients enrolled in three consecutive Italian protocols has progressively improved, as a result of intensive chemotherapy, delayed surgery and, possibly, HART, though improved imaging and radiotherapeutic tools may have had a role as well.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Humans. Infant. Male. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18300319.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Vaupel P, Kelleher DK, Höckel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol; 2001 Apr;28(2 Suppl 8):29-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.
  • Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature;.
  • (2) an increase in diffusion distances; and (3) tumor- or therapy-associated anemia leading to a reduced O2 transport capacity of the blood.
  • There is pronounced intertumor variability in the extent of hypoxia, which is independent of clinical size, stage, histopathologic type, and grade.
  • Tumor hypoxia is intensified in anemic patients, especially in tumors with low perfusion rates.
  • Tumor hypoxia is a therapeutic problem, as it makes solid tumors resistant to sparsely ionizing radiation and some forms of chemotherapy.
  • Hypoxia also may modulate the proliferation and cell cycle position of tumor cells and, in turn, the amount of cells destroyed following therapy.
  • Recent clinical studies suggest that hypoxia can enhance malignant progression and increase aggressiveness through clonal selection and genome changes.
  • As a result, loss of differentiation and apoptosis, chaotic angiogenesis, increased locoregional spread, and enhanced metastasis can further increase resistance to therapy and affect long-term prognosis.
  • Hypoxia is a powerful, independent prognostic factor in cervix cancers, carcinomas of the head and neck, and in soft-tissue sarcomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11395850.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


14. Yang XJ, Zheng JW, Zhou Q, Ye WM, Wang YA, Zhu HG, Wang LZ, Zhang ZY: Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients. Int J Oral Maxillofac Surg; 2010 Jun;39(6):568-72
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcomas of the head and neck: a clinico-immunohistochemical study of 8 consecutive patients.
  • Angiosarcoma, also known as malignant hemangioendothelioma, is a rare and aggressive malignant vascular tumour arising from endothelial cells, which accounts for approximately 10% of soft tissue sarcomas in the head and neck.
  • Between October 1996 and July 2008, 10 patients were diagnosed with angiosarcomas (AS) in the head and neck region, 8 of whom were included in this study (there were 7 high-grade and 1 low-grade lesions).
  • Six patients were treated surgically with or without postoperative radiotherapy and/or chemotherapy.
  • Two patients had large and extensive lesions that were considered to be inoperable, they were given palliative chemotherapy and/or radiotherapy.
  • Of the 8 patients reviewed in this study, 5 died of local recurrence or distant metastasis with a survival time of 8-19 months, 2 patients are alive with disease and 1 patient is free of disease.
  • The predeliction for local recurrence and distant metastasis and the high-grade characteristics of this tumour seemed to be correlated to the poor prognosis, although the small number of patients prevented statistical analysis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Head and Neck Neoplasms / chemistry. Head and Neck Neoplasms / pathology. Hemangiosarcoma / chemistry. Hemangiosarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Antigens, Neoplasm / analysis. Factor VIII / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413272.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 9001-27-8 / Factor VIII
  •  go-up   go-down


15. Ilgner J, Rojas W, Biesterfeld S, Schürmann K, Zimny M, Westhofen M: [Low-grade malignant peripheral nerve sheath tumor of the neck soft tissues]. Laryngorhinootologie; 2001 Jan;80(1):39-42
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-grade malignant peripheral nerve sheath tumor of the neck soft tissues].
  • BACKGROUND: Malignant Peripheral Nerve Sheath Tumours (MPNST) either grow sporadically, after radiation or chemotherapy respectively.
  • Because of the multiform histologic picture they are often difficult to differentiate from other soft tissue tumours.
  • PATIENT: We present the case of a sporadic MPNST which developed from the vagus nerve of a 39-year-old patient following radiation of the neck 7 years before.
  • RESULTS AND CONCLUSIONS: Sporadic MPNST of the head and neck are comparatively rare.
  • With regard to the strong association with Neurofibromatosis I and the difficult differential diagnosis to other soft tissue tumours the emphasis should be put on excluding further manifestations of Neurofibromatosis I and of secondary tumours.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Head and Neck Neoplasms / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Nerve Sheath Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis. Vagus Nerve Diseases / diagnosis
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Female. Humans. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / surgery. Vagus Nerve / pathology

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11272246.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Paikos P, Papathanassiou M, Stefanaki K, Fotopoulou M, Grigorios S, Tzortzatou F: Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature. Surv Ophthalmol; 2002 Jul-Aug;47(4):368-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature.
  • Malignant ectomesenchymoma is a rare soft tissue tumor of childhood composed of both mesenchymal and neuroectodermal elements.
  • Reported sites of origin are head and neck, abdomen, perineum, scrotum, and extremities.
  • The clinical picture of the tumor, radiological findings, and its histopathologic and immunohistochemical characteristics are described.
  • The patient was successfully treated with combined surgical resection and chemotherapy.
  • All the other reported cases of malignant ectomesenchymoma with various sites of origin are also reviewed.
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161212.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


17. Chigurupati R, Alfatooni A, Myall RW, Hawkins D, Oda D: Orofacial rhabdomyosarcoma in neonates and young children: a review of literature and management of four cases. Oral Oncol; 2002 Jul;38(5):508-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma (RMS) is an aggressive malignant skeletal muscle neoplasm arising from embryonal mesenchyme.
  • It accounts for over 50% of all pediatric soft tissue sarcomas.
  • The head and neck region is the most common site for this tumor in children.
  • Neonatal presentation of this tumor is rare.
  • Three of the four cases were alveolar RMS and one was botryoid sub-type of embryonal RMS.
  • Three patients were treated with a combination of surgery, chemotherapy and radiation, while the patient with botryoid RMS was treated with surgery and chemotherapy only.
  • We discuss the current management, diagnosis, biological behavior, histopathology, prognosis and survival of head and neck RMS in neonates and young children.
  • [MeSH-major] Facial Neoplasms / therapy. Mouth Neoplasms / therapy. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12110348.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


18. Park YM, Cho JH, Cho JY, Huh JS, Ahn JY: Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. World J Surg Oncol; 2007;5:86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Isolated oculomotor nerve palsy is uncommon as an initial presentation of malignant tumors of the sphenoid sinus.
  • Magnetic Resonance Imaging (MRI) demonstrated a homogenous soft-tissue lesion occupying the left sphenoid sinus and invading the left cavernous sinus.
  • The patient underwent transsphenoidal biopsy and the lesion was histologically diagnosed as non-Hodgkin's lymphoma, diffuse large B-cell type.
  • Tumor cells were positive for CD20 and negative for CD3.
  • Following six cycles of chemotherapy, the left oculomotor nerve palsy that had been previously observed was completely resolved.
  • The cranial nerve deficits can resolve dramatically after chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurochirurgie. 2002 Dec;48(6):522-6 [12595809.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Acta Neurol Belg. 2000 Jun;100(2):103-6 [10934562.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Am J Ophthalmol. 2000 Feb;129(2):256-8 [10682985.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 May;120(5):730-6 [10229601.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Radiology. 1997 Aug;204(2):431-5 [9240531.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1995;112(6):298-302 [8561414.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Apr;102(4 Pt 1):318-21 [8476174.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):222-5 [1590274.001]
  • [Cites] No Shinkei Geka. 1992 Mar;20(3):283-7 [1557180.001]
  • [Cites] Radiology. 1988 Jun;167(3):803-8 [3363145.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Feb;11(2):357-64 [3882644.001]
  • [Cites] Am J Clin Pathol. 1984 Jun;81(6):721-7 [6547270.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1925-31 [7427898.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):11-9 [12633576.001]
  • [Cites] Cancer. 1978 Aug;42(2):406-16 [679145.001]
  • (PMID = 17683562.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950883
  • [General-notes] NLM/ Original DateCompleted: 20070828
  •  go-up   go-down


19. Vasanawala MS, Wang Y, Quon A, Gambhir SS: F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med; 2006 Sep;31(9):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous angiosarcoma of the scalp is a rare highly aggressive malignant tumor that typically afflicts elderly patients and commonly presents with extensive local spread and distant metastasis.
  • It differs from other soft tissue sarcomas in that the size of the lesion at presentation instead of tumor grade is the important prognostic factor.
  • Optimal treatment is yet to be determined.
  • Wide-margin complete excision with postoperative radiotherapy has been the most effective therapy.
  • Chemotherapy and gene therapy have been used with some success.
  • Local extent is critical in surgical planning, especially in the head and face, and is difficult to determine accurately with clinical examination and morphologic imaging tools.
  • PET/CT imaging after chemotherapy and before radiation therapy showed complete resolution of FDG uptake in the scalp and osseous lesions.
  • Evaluation of more cases of this subset of soft tissue sarcoma with FDG PET/CT may suggest a possible role in not only staging angiosarcomas to determine the extent of local as well as distant disease, but also to potentially help determine response to therapy and early recognition of local or distant recurrence.
  • [MeSH-major] Fluorodeoxyglucose F18. Hemangiosarcoma / diagnosis. Hemangiosarcoma / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Radiopharmaceuticals. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921276.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Carvalho JR, Haddad L, Leonhardt FD, Marques Filho MF, Santos Rde O, Cervantes O, Abrahão M: Head and neck hemangiopericytoma in a child: case report. Sao Paulo Med J; 2004 Sep 2;122(5):223-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck hemangiopericytoma in a child: case report.
  • CONTEXT: Hemangiopericytoma is a relatively rare tumor, first described in 1942, with approximately 300 cases described in the literature to date.
  • The head and neck incidence is less than 20%, mostly in adults.
  • We describe a case of malignant head and neck hemangiopericytoma in a child.
  • TYPE OF STUDY: Case report.
  • During dental treatment one month later, a cranial x-ray revealed bone alterations.
  • A subsequent computed tomography scan showed an extensive lesion of soft tissue density that had invaded the maxillary fossa, eroding the skull base and middle and nasal fossa.
  • The child was then referred to our service, where biopsy was performed, giving a diagnosis of hemangiopericytoma.
  • The patient was submitted to conservative surgery in April 2001, with only partial resection of the tumor because of its extent.
  • Histopathological examination of the specimen confirmed the presence of malignant hemangiopericytoma.
  • Following the surgery, the patient presented fast regrowth of the lesion, with partial response to chemotherapy and radiotherapy.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hemangiopericytoma / diagnosis
  • [MeSH-minor] Adult. Angiography. Child. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558145.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


21. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, Coray A, Jermann M, Rutz HP, Goitein G: Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys; 2007 Feb 1;67(2):497-504
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute.
  • PURPOSE: Radiotherapy plays a major role in the treatment strategy of childhood sarcomas.
  • Consequences of treatment are likely to affect the survivor's quality of life significantly.
  • We investigated the feasibility of spot-scanning proton therapy (PT) for soft tissue tumors in childhood.
  • METHODS AND MATERIALS: Sixteen children with soft tissue sarcomas were included.
  • In 10 children the tumor histology was embryonal rhabdomyosarcoma.
  • All tumors were located in the head or neck, parameningeal, or paraspinal, or pelvic region.
  • In the majority of children, the tumor was initially unresectable (Intergroup Rhabdomyosarcoma Study [IRS] Group III in 75%).
  • Fourteen children had chemotherapy before and during PT.
  • All 16 children were treated with spot-scanning proton therapy at the Paul Scherrer Institute, and in 3 children the PT was intensity-modulated (IMPT).
  • All 4 children died of tumor recurrence.
  • All 4 showed unfavorable characteristic either of site or histopathology of the tumor.
  • Acute toxicity was low, with Grade 3 or 4 side effects according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria occurring in the bone marrow only.
  • CONCLUSIONS: Proton therapy was feasible and well tolerated.
  • [MeSH-major] Protons / therapeutic use. Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / radiotherapy. Humans. Infant. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / mortality. Meningeal Neoplasms / radiotherapy. Quality of Life. Radiation Injuries / pathology. Rhabdomyosarcoma, Embryonal / drug therapy. Rhabdomyosarcoma, Embryonal / mortality. Rhabdomyosarcoma, Embryonal / radiotherapy. Spinal Neoplasms / drug therapy. Spinal Neoplasms / mortality. Spinal Neoplasms / radiotherapy. Survivors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084557.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


22. Inci E, Korkut N, Erem M, Kalekoğlu N: [Alveolar soft tissue sarcoma]. HNO; 2004 Feb;52(2):145-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alveolar soft tissue sarcoma].
  • Alveolar soft part sarcoma is a malignant soft part tumor the etiology of which has not yet been clarified.
  • PAS-positive, diastase resistant intraplasmic inclusion bodies are characteristic for this tumor which occurs in the head and neck region; mainly the tongue and the orbita.
  • Primary therapy includes total resection which can later be combined with radiotherapy or chemotherapy.
  • We totally removed the tumor and then used radiotherapy.
  • [MeSH-major] Magnetic Resonance Angiography. Magnetic Resonance Imaging. Oropharyngeal Neoplasms / diagnosis. Sarcoma, Alveolar Soft Part / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Embolization, Therapeutic. Female. Follow-Up Studies. Humans. Neoadjuvant Therapy. Neovascularization, Pathologic / diagnosis. Neovascularization, Pathologic / therapy. Oropharynx / blood supply. Oropharynx / pathology. Oropharynx / surgery. Radiotherapy, Adjuvant. Sclerotherapy. Tongue / blood supply. Tongue / pathology. Tongue / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jun;65(6):742-4 [3041338.001]
  • [Cites] Int J Oral Maxillofac Surg. 1990 Apr;19(2):110-2 [2111358.001]
  • [Cites] Hum Pathol. 1982 Jun;13(6):569-79 [7076238.001]
  • [Cites] Head Neck Surg. 1987 Jan-Feb;9(3):172-8 [3623948.001]
  • [Cites] JAMA. 1966 Dec 5;198(10):1047-51 [5953380.001]
  • [Cites] J Oral Maxillofac Surg. 1995 Oct;53(10):1203-8 [7562177.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1998 Sep;107(9 Pt 1):810-4 [9749554.001]
  • [Cites] AJR Am J Roentgenol. 1989 Aug;153(2):335-9 [2750619.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):58-68 [8202647.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):81-4 [8531857.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):507-14 [7093893.001]
  • [Cites] Skeletal Radiol. 1995 May;24(4):267-70 [7644939.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1989 May;17(2):139-53 [2759779.001]
  • [Cites] Clin Radiol. 1992 Oct;46(4):253-6 [1424447.001]
  • [Cites] Int J Oral Maxillofac Surg. 2000 Oct;29(5):370-2 [11071242.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):1-13 [2642727.001]
  • [Cites] Histopathology. 1993 Nov;23(5):439-44 [8314217.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1984 May;57(5):532-9 [6587301.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Dec;37(6):451-4 [10687905.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1988 May-Jun;97(3 Pt 1):328-9 [3377402.001]
  • [Cites] Cancer. 1952 Jan;5(1):100-11 [14886902.001]
  • (PMID = 14968318.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Mevio E, Sbrocca M, Gorini E, Artesi L, Mullace M, Castelli A, Migliorini L: Malignant fibrous histiocytoma of the pharynx. Acta Otorhinolaryngol Belg; 2003;57(1):79-81
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the pharynx.
  • Malignant fibrous histiocytoma (MFH) is the most common soft-tissue sarcoma of late adult life, but is relatively uncommon in the head and neck region.
  • That region has been reported to be the origin of malignant fibrous histiocytoma in 3-10% of cases.
  • Only one case of the tumor occurring in the pharynx has been reported.
  • Histologically it is sometimes hard to distinguish this tumor from some sarcomas and pleomorphic carcinomas.
  • The treatment of choice is a large surgical resection, while radiotherapy and chemotherapy are reserved for recurrences.
  • The authors present a case of oropharyngeal malignant fibrous histiocytoma.
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12642957.001).
  • [ISSN] 0001-6497
  • [Journal-full-title] Acta oto-rhino-laryngologica Belgica
  • [ISO-abbreviation] Acta Otorhinolaryngol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


24. Pellitteri PK, Ferlito A, Bradley PJ, Shaha AR, Rinaldo A: Management of sarcomas of the head and neck in adults. Oral Oncol; 2003 Jan;39(1):2-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of sarcomas of the head and neck in adults.
  • Sarcomas account for less than 1% of all malignant neoplasms occurring in the head and neck in adults.
  • The pattern of growth demonstrated by sarcomas is generally by local advancement with high-grade tumor exhibiting extensive involvement of adjacent visceral and neurovascular structures.
  • The clinical presentation of these neoplasms is variable and dependent on subsite of involvement as well as the aggressiveness of tumor growth.
  • Histologic diagnosis is frequently challenging, often requiring the aid of immunohistochemical staining techniques.
  • Treatment is predominantly surgical, utilizing wide local excision where en-bloc resection is feasible.
  • Chemotherapy regimens are available for soft tissue neoplasms and osteosarcoma and are primarily designed to improve local control.
  • Survival is predicted on the incidence of local recurrence and risk of distant metastasis, both of which are influenced by tumor grade.
  • [MeSH-major] Head and Neck Neoplasms. Sarcoma
  • [MeSH-minor] Humans. Neoplasms, Radiation-Induced / etiology. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12457715.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


25. Sbeity S, Abella A, Arcand P, Quintal MC, Saliba I: Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol; 2007 May;71(5):807-14
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric age group.
  • The twofold objective of this study is to illustrate the clinical presentation, management, and prognosis of this malignant striated muscle tumor, and to compare these results with previously reported series.
  • METHODS: A retrospective study was conducted of patients diagnosed and treated for rhabdomyosarcoma of the head and neck at Saint Justine Hospital, a tertiary pediatric center, between 1970 and 2005.
  • A thorough review of medical and surgical charts was performed to obtain demographic, clinical, paraclinical, and therapeutic data, which were subsequently analyzed and compared to published results.
  • RESULTS: Thirty-nine patients with rhabdomyosarcoma of the head and neck region were identified, among which only six children had temporal bone rhabdomyosarcoma.
  • The mean age at the time of diagnosis was 4.15 years.
  • All patients except two received combined chemotherapy and radiotherapy as treatment.
  • CONCLUSION: Rhabdomyosarcoma of the temporal bone is an aggressive tumor that clinically simulates chronic otitis media.
  • A high index of suspicion should be raised in the context of otitis media that is unresponsive to ordinary medical treatment.
  • A biopsy is hence recommended in the presence of polyps in the external auditory canal that are resistant to medical treatment.
  • Early diagnosis and the adoption of multimodal therapy offer the best outcome.
  • [MeSH-minor] Adolescent. Child, Preschool. Chronic Disease. Female. Humans. Male. Neoplasm Staging. Otitis Media / etiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17346806.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


26. Woźniak AW, Nowaczyk MT, Osmola K, Golusinski W: Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature. Eur Arch Otorhinolaryngol; 2010 Jun;267(6):845-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of an osteoblastoma of the mandible: case report and review of the literature.
  • Benign osteoblastoma is a rarely seen tumor of the facial bones.
  • The authors present a case of a 30-year-old man with a tumor of the mandibular body and ramus.
  • The histopathological diagnosis was one of osteoblastoma.
  • Postoperative recurrence with soft tissue infiltration suggested an osteosarcoma radiologically, but the histological examination again revealed the presence of an osteoblastoma.
  • A second recurrence occured in the pharyngo-glossal region and this time the tumor was histologically diagnosed as an osteoblastoma, but with foci of well-differentiated osteosarcoma.
  • The patient was given a course of radiotherapy, but clinical and radiological examination 8 months later revealed lung metastases and chemotherapy was started.
  • While osteoblastomas are rare, and their sarcomatous change even rarer, our experience with this case lead us to suggest that a therapeutic preventative approach, involving both chemotherapy and total excision of the tumor, is the regime to adopt with osteoblastomas which involve soft tissues and have radiological features suggesting malignancy.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteoblastoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Male. Mandible / pathology. Mandible / surgery. Radiography, Panoramic. Radiotherapy, Adjuvant. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Spine J. 1998;7(3):246-8 [9684960.001]
  • [Cites] J Clin Pathol. 1993 Nov;46(11):1024-9 [8254089.001]
  • [Cites] Neurosurg Rev. 1997;20(1):51-4 [9085288.001]
  • [Cites] Histopathology. 1997 Aug;31(2):196-200 [9279574.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):305-9 [9078333.001]
  • [Cites] Skeletal Radiol. 1994 Oct;23 (7):509-12 [7824976.001]
  • [Cites] J Neurosurg. 1991 Jul;75(1):138-42 [2045899.001]
  • [Cites] Gen Diagn Pathol. 1996 May;141(5-6):377-92 [8780939.001]
  • [Cites] Eur J Radiol. 1998 May;27 Suppl 1:S91-7 [9652508.001]
  • [Cites] Skeletal Radiol. 1994 Nov;23 (8):656-9 [7886478.001]
  • [Cites] Aktuelle Radiol. 1996 Nov;6(6):338-40 [9081408.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):416-26 [3855268.001]
  • [Cites] J Comput Assist Tomogr. 1996 Jan-Feb;20(1):116-8 [8576460.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):117-34 [8119712.001]
  • [Cites] Chirurg. 2002 Dec;73(12 ):1181-90 [12491047.001]
  • [Cites] Arq Neuropsiquiatr. 1998 Jun;56(2):292-5 [9698743.001]
  • [Cites] J Laryngol Otol. 1997 Sep;111(9):865-8 [9373556.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jan;52(1):86-90 [8263651.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Feb;18(2):324-6 [9111670.001]
  • [Cites] Surg Neurol. 1998 Mar;49(3):274-7 [9508114.001]
  • (PMID = 20012077.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 20
  •  go-up   go-down


27. Orzechowska-Wylegała B, Kajor M, Mazur M, Wodołazski A, Malara P, Drugacz J: [Malignant lymphoma or inflammation? Diagnostic and treatment difficulties--2 cases report]. Pol Merkur Lekarski; 2006 Apr;20(118):433-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma or inflammation? Diagnostic and treatment difficulties--2 cases report].
  • Soft and hard tissue in the oral cavity can be the first coexisting place of systemic diseases manifestation.
  • The aim of this study was to report the diagnostic and treatment difficulties in two patients with malignant lymphomas.
  • The first case was a 66-year-old woman who had undergone surgery procedures connected with radiotherapy and chemotherapy because of malignant lymphoma in nasal cavity in 2001 year.
  • In 2002 she was treated in our department after finding tumor in oral cavity, also diagnosed as malignant lymphoma.
  • The second patient was a 58-year-old man who had undergone an operation (surgery) by reason of maxillary inflammation tumor in 2002 year.
  • On the next year he underwent an operation of removal cervical lymp nodes because of malignant lymphoma.
  • In 2004 year he underwent surgery on account of maxillary tumor suspected by malignant lymphoma, which was diagnosed as inflammation.
  • Conclusions. In differentiation tumors of head and neck one should take an account of lymphoma malignant.
  • The similar clinic and radiological symptoms and laboratory results of malignant lymphomas and inflammations of head and neck can cause the late diagnosis and aggravate the prognosis of this severe disease.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Inflammation / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886569.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is an increased incidence of second malignant neoplasms in survivors of childhood cancers.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • Although, ionizing radiation has been demonstrated to increase the risk of developing a salivary gland neoplasm, there are few reports of salivary gland neoplasms occurring in patients treated for cancer in childhood.
  • RESULTS: Twelve survivors of childhood cancer developed a salivary gland neoplasm after completion of treatment.
  • These patients were initially treated for a variety of childhood cancers with a combination of radiation and chemotherapy.
  • All patients were treated with surgical excision of the primary tumor, and postoperative radiation was added in select patients.
  • CONCLUSION: Radiation and chemotherapy used to treat patients with childhood malignancies increases the risk of developing a second neoplasm of salivary gland origin.
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • The treatment of these tumors includes surgical excision of the primary, with neck dissection in patients with clinical evidence of nodal metastasis, and postoperative radiation added for pathologies with adverse features.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


29. Thanni LO: Extremity haemangiopericytoma, a case report from Nigeria. Afr Health Sci; 2005 Sep;5(3):261-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Haemangiopericytoma is an uncommon soft tissue sarcoma of vascular origin.
  • Wide surgical excision is the mainstay of treatment.
  • However, adjuvant radiotherapy and chemotherapy are desirable because the malignant nature of this tumour is frequently unpredictable.
  • Adjuvant therapy is recommended for metastases, recurrence and incomplete resection.
  • Long term follow up is essential in all cases as recurrence can occur several years after treatment.
  • Where little or no experience with managing this tumor exists, it is important to be aware of its clinical behaviour and the treatment options, hence this case reports.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Leg / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Formos Med Assoc. 2000 May;99(5):428-30 [10870335.001]
  • [Cites] Radiology. 1960 May;74:721-30 [13825130.001]
  • [Cites] Head Neck. 2004 Jun;26(6):544-9 [15162357.001]
  • [Cites] J Foot Ankle Surg. 2004 May-Jun;43(3):191-4 [15181437.001]
  • [Cites] J Reprod Med. 2004 May;49(5):404-7 [15214720.001]
  • [Cites] Tumori. 2004 Mar-Apr;90(2):265-8 [15237597.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):128-32 [4359454.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Am J Surg. 1979 Mar;137(3):413-6 [434338.001]
  • [Cites] Am J Surg. 1984 Sep;148(3):372-4 [6476228.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1989 Sep-Oct;127(5):611-5 [2596154.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 1998 Jun;46(6):523-5 [9720371.001]
  • [Cites] Int Orthop. 1999;23(3):184-6 [10486035.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):315-9 [15243738.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):159-66 [12860507.001]
  • (PMID = 16245998.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831924
  •  go-up   go-down


30. Fleshman R, Mayerson J, Wakely PE Jr: Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer; 2007 Dec 25;111(6):491-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They also searched their tissue database for all HGS cases that had prior FNA biopsy findings.
  • RESULTS: A total of 107 FNA samples from 98 patients (age range, 13-90 years, with a male:female ratio of 1:1) had an FNA diagnosis of HGS, or had HGS and a prior FNA diagnosis of another entity.
  • The positive predictive value of an FNA diagnosis of HGS was 97% (88 of 91 cases).
  • Fifty-four cases were diagnosed as HGS, not otherwise specified, 8 as myxofibrosarcoma, 8 as osteosarcoma, 5 as malignant peripheral nerve sheath tumor, 5 as leiomyosarcoma, 4 as Ewing sarcoma, 4 as liposarcoma, 2 as epithelioid sarcoma, and 1 as angiosarcoma.
  • Approximately 71% of patients presented with a primary tumor, 23% with disease recurrence, and 7% with metastasis.
  • Sites of disease included the lower extremity (59%), upper extremity (19%), trunk (15%), groin (4%), and head and neck (4%).
  • FNA diagnosis was confirmed histologically in 88% of cases, clinically in 7% of cases, and cytogenetically in 1% of cases; 3% of cases had false-positive results and 1 patient was lost to follow-up.
  • Sixteen of 19 patients received neoadjuvant chemotherapy based on the FNA diagnosis alone.
  • CONCLUSIONS: A cytopathologic diagnosis of HGS was found to be accurate in 88 of 97 cases (91%) with follow-up.
  • A FNA biopsy diagnosis of HGS appears to be clinically reliable in a high percentage of cases when used in close conjunction with the orthopedic team.
  • [MeSH-major] Biopsy, Fine-Needle. Cytodiagnosis. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941014.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor].
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • One or two cycles of neoadjuvant chemotherapy were used to each of the patients before operation.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • The patient with malignant fibrous histocytoma died of systemic metastasis 20 months after operation.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • The patient with osteosarcoma underwent amputation 12 months after operation because of the tumor recurrence.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Siveke JT, Sen Gupta R, Rieckhoff KU, Braumann D, Goldmann T: [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor]. HNO; 2003 Oct;51(10):825-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progressive paralysis caused by radiation-induced cervical malignant peripheral nerve sheath tumor].
  • HISTORY AND DIAGNOSIS: A 59-year old engineer was admitted to the hospital because of pain in his right collar region and the onset of incomplete paresis of the right arm.
  • Magnetic resonance tomography displayed an advanced tumour arising from the right paravertebral soft tissue.
  • Histological examination revealed a malignant peripheral nerve sheath tumor (MPNST).
  • Thirteen years before admission, the patient had a right-sided tumor-tonsillectomy of a squamous cell carcinoma and local radiation of a cystic squamous cell carcinoma in the ipsilateral cervical soft tissue.
  • CLINICAL COURSE AND THERAPY: In the following course, progressive neurological symptoms occurred including beginning paraplegia, right phrenic paralysis and a severe concomitant pain syndrome.
  • Due to the location and advanced tumor state, surgical treatment was not performed and palliative chemotherapy remained ineffective.
  • Unusual neurological symptoms in anatomical regions of former radiation should therefore include neurogenic secondary malignancies in the differential diagnosis for early surgical intervention.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / diagnosis. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Nerve Sheath Neoplasms / diagnosis. Paraparesis / etiology. Radioisotope Teletherapy / adverse effects. Tonsillar Neoplasms / radiotherapy
  • [MeSH-minor] Arm / innervation. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Respiratory Paralysis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - paralysis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1247-53 [8435801.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1028-33 [6821867.001]
  • [Cites] Eur J Cancer. 1995;31A(1):31-4 [7695975.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61 [10571202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 14523537.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Tejada-Berges T, Granai CO, Gordinier M, Gajewski W: Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther; 2002 Apr;2(2):143-50
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.
  • This, coupled with a small vesicular size, uniquely promotes the localization of Caelyx/Doxil at tumor sites and explains its altered toxicity profile.
  • The FDA and EMEA have approved its use for the treatment of AIDS-related Kaposi's sarcoma and, more recently, for recurrent epithelial ovarian cancer (EOC).
  • Numerous investigations have focused on its use in the treatment of metastatic breast cancer, as well as recurrent squamous cell cervical carcinoma, soft tissue sarcoma, squamous head and neck cancers, prostate cancers and malignant gliomas.
  • Ongoing clinical studies of combination regimens incorporating Caelyx/Doxil will further clarify its role in the treatment of advanced solid tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / drug therapy. Doxorubicin / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic / methods. Clinical Trials as Topic / statistics & numerical data. Female. Humans. Neoplasm Recurrence, Local / drug therapy


34. Fu ZC, Zhang B, Fu ZJ: As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland. Med Hypotheses; 2010 Dec;75(6):490-1
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland.
  • Adenoid cystic carcinoma (ACC) is an uncommon tumor of the head and neck that may occur in any salivary gland tissue.
  • Discouraging treatment outcomes may be related to perineural spread, loco regional invasion, and an unusually high incidence of metastatic potential.
  • It presents a number of challenges related to facial nerve management and disease extension into surrounding soft tissue and bony compartments.
  • It is a high malignant carcinoma characterized by intensive local invasion and insidious distant metastasis to the lung at an early stage, which is responsible for a poor long-term survival rate.
  • The main clinical treatment to adenoid cystic carcinoma depended on surgical operation in the past.
  • However, it was not so easy to completely excise adenoid cystic carcinoma which resulting in the residual of tumor cells.
  • Adenoid cystic carcinoma is not sensitive to conventional chemotherapeutics, so it is necessary to explore a new kind of drug which possesses inhibition and killing effects to this tumor.
  • Arsenic trioxide (A(S2)O(3), ATO), a trivalent inorganic arsenite, has been proved to be an effective therapeutic agent against acute promyelocytic leukemia.
  • Numerous reports have revealed that arsenite exerts its therapeutic activity by induction of apoptosis.
  • A(S2)O(3) may become a treatment option for adenoid cystic carcinoma of salivary gland.
  • [MeSH-major] Apoptosis / drug effects. Arsenicals / therapeutic use. Carcinoma, Adenoid Cystic / drug therapy. Growth Inhibitors / therapeutic use. Oxides / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656411.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Growth Inhibitors; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


35. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C: Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res; 2006 Dec 15;12(24):7444-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The angiogenic phenotype of malignant cancers has been established as a target for cancer therapy.
  • ABT-526 and ABT-510, two peptide mimetics of thrombospondin-1 (TSP-1), block angiogenesis in vitro and in vivo and slow tumor growth in mice.
  • To guide the clinical development of these drugs, translational studies in dogs with naturally occurring cancers were initiated.
  • EXPERIMENTAL DESIGN: A prospective open-label trial using ABT-510 or ABT-526 in pet dogs with measurable malignant spontaneously arising tumors.
  • Forty-two dogs receiving peptide had objective responses (>50% reduction in tumor size; n = 6) or significant disease stabilization.
  • Antitumor activity was similar for both peptides and was seen in several histologies, including mammary carcinoma, head and neck carcinoma, soft tissue sarcoma, cutaneous T-cell lymphoma, and non-Hodgkin's lymphoma.
  • CONCLUSIONS: These results support the safety and activity of ABT-526 and ABT-510 in dogs with naturally occurring malignant cancers.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neoplasms / drug therapy. Oligopeptides / therapeutic use. Peptide Fragments / therapeutic use. Thrombospondin 1 / therapeutic use
  • [MeSH-minor] Animals. Cell Movement / drug effects. Dogs. Drug Screening Assays, Antitumor. Endothelial Cells / drug effects. Female. Humans. Male. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189418.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt; 0 / Oligopeptides; 0 / Peptide Fragments; 0 / Thrombospondin 1; 0 / acetyl-sarcosyl-glycyl-valyl-isoleucyl-threonyl-norvalyl-isoleucyl-arginyl-proline ethylamide
  •  go-up   go-down


36. Olsen RJ, Tarantolo SR, Hinrichs SH: Molecular approaches to sarcoma therapy. Sarcoma; 2002;6(1):27-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular approaches to sarcoma therapy.
  • Soft tissue sarcomas comprise a heterogeneous group of aggressive tumors that have a relatively poor prognosis.
  • Although conventional therapeutic regimens can effectively cytoreduce the overall tumor mass, they fail to consistently achieve a curative outcome.
  • Alternative gene-based approaches that counteract the underlying neoplastic process by eliminating the clonal aberrations that potentiate malignant behavior have been proposed.
  • Secondary gene mutations may provide an additional growth advantage that further contributes to malignant progression.
  • The recent clinical success of the tyrosine kinase inhibitor, STI571, suggests that therapeutic approaches specifically directed against essential survival factors in sarcoma cells may be effective.
  • (3) restoration of tumor suppressor function;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Jan;162 Suppl:S23-S32 [11164187.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):841-2 [11248162.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):691-6 [11249747.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1084-6 [11287980.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2641-8 [11289142.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):354-60 [11291071.001]
  • [Cites] Oncogene. 2001 Mar 29;20(14):1756-64 [11313922.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1096-103 [11378339.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6194-9 [1423262.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3402-8 [1596900.001]
  • [Cites] Cell. 1992 Aug 7;70(3):375-87 [1643656.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] Sarcoma. 1998;2(1):3-17 [18521227.001]
  • [Cites] Sarcoma. 1998;2(2):77-87 [18521238.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):101-6 [2009504.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):423-31 [7845667.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):345-55 [8053493.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9901-5 [8234333.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):13-7 [8265096.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):469-75 [7640234.001]
  • [Cites] Clin Orthop Relat Res. 1995 Jan;(310):176-87 [7641436.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Oncogene. 1995 May 4;10(9):1749-56 [7753552.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1428-32 [10197607.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):690-5 [10354133.001]
  • [Cites] Oncol Res. 1998;10(11-12):541-50 [10367935.001]
  • [Cites] Cancer Lett. 1999 May 24;139(2):159-65 [10395173.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3100-6 [10397251.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):11-22 [10402634.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):47-51 [10402637.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):72-7 [10402640.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):78-82 [10402641.001]
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):267-74 [10416879.001]
  • [Cites] Curr Opin Oncol. 1999 Jul;11(4):275-84 [10416880.001]
  • [Cites] Am J Dermatopathol. 1999 Aug;21(4):392-4 [10446785.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] Surgery. 1999 Aug;126(2):399-405 [10455913.001]
  • [Cites] Hum Gene Ther. 1999 Sep 20;10(14):2325-35 [10515452.001]
  • [Cites] Gene. 1999 Sep 17;237(2):281-302 [10521653.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2963-70 [10537366.001]
  • [Cites] Curr Opin Oncol. 1996 Jul;8(4):284-8 [8869802.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13164-9 [8917562.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] EXS. 1997;79:1-8 [9002217.001]
  • [Cites] J Clin Invest. 1997 Jan 15;99(2):239-47 [9005992.001]
  • [Cites] Nucleic Acids Res. 1997 Jan 1;25(1):151-7 [9016527.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Dec;7(4):311-25 [9023055.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):9-16 [9049825.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):429-37 [9052984.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2543-50 [9058785.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1259-68 [9178886.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2250-8 [9278313.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):735-44 [9284822.001]
  • [Cites] Semin Cancer Biol. 1997 Apr;8(2):113-9 [9299589.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14701-6 [9405676.001]
  • [Cites] Oncogene. 1997 Dec 4;15(23):2855-66 [9419977.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):20-2 [9426050.001]
  • [Cites] N Engl J Med. 1998 Jan 15;338(3):153-60 [9428816.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):145-52 [9516963.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1248-55 [9552022.001]
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):148-54 [10550840.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1125-31 [10568818.001]
  • [Cites] Med Pediatr Oncol. 1999 Dec;33(6):530-5 [10573575.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34811-8 [10574952.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5745-50 [10582694.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Nov-Dec;16(6):539-44 [10599094.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7681-9 [10618708.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] JAMA. 2000 Jan 19;283(3):317, 321 [10647784.001]
  • [Cites] Somat Cell Mol Genet. 1998 Sep;24(5):281-9 [10696236.001]
  • [Cites] Diagn Mol Pathol. 2000 Mar;9(1):9-13 [10718207.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1326-31 [10728694.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Jan;30(1):27-38 [9597751.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16874-9 [9642248.001]
  • [Cites] Curr Opin Oncol. 1998 Jul;10(4):318-25 [9702399.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1026-32 [9706984.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1985-94 [9717829.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4185-92 [9751633.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1391-5 [9816312.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(10):532-40 [9829856.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1937-45 [9846983.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):55-63 [10889903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8490-4 [10890910.001]
  • [Cites] Head Neck. 2000 Aug;22(5):483-8 [10897108.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3655-61 [10910082.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1998 Jul;20(4):280-3 [10920984.001]
  • [Cites] Int J Cancer. 2000 Oct 15;88(2):252-9 [11004677.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):731-8 [11012987.001]
  • [Cites] Physiol Genomics. 1999 Nov 11;1(3):127-38 [11015571.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5117-24 [11016638.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5134-42 [11016640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12547-52 [11070080.001]
  • [Cites] Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):153-66 [11072112.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6160-70 [11085540.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Dec 20;279(2):401-6 [11118299.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4848-58 [11156244.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6964-71 [11156397.001]
  • [Cites] J Mol Biol. 2001 Feb 2;305(5):989-1010 [11162109.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):675-82 [8616759.001]
  • [Cites] Cancer Lett. 1996 Feb 27;100(1-2):63-9 [8620455.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Biol Chem. 1996 Apr 5;271(14):8008-14 [8626482.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2137-43 [10928167.001]
  • [Cites] Mol Ther. 2000 Jan;1(1):71-81 [10933914.001]
  • [Cites] Mol Ther. 2000 May;1(5 Pt 1):457-63 [10933967.001]
  • [Cites] Mol Ther. 2000 Jun;1(6):555-65 [10933980.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1097-104 [10935650.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):783-92 [10951341.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):793-9 [10951342.001]
  • [Cites] Oncogene. 2000 Aug 10;19(34):3878-87 [10951581.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3056-61 [10955784.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):194-203 [10968705.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4311-4 [10969766.001]
  • [Cites] J Orthop Sci. 2000;5(4):418-23 [10982695.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Forum (Genova). 1998 Oct-Dec;8(4):368-76 [9863031.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5842-9 [9865744.001]
  • [Cites] Exp Cell Res. 1999 Jan 10;246(1):38-46 [9882513.001]
  • [Cites] Clin Chem. 1999 Jan;45(1):7-17 [9895331.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):551-7 [9927212.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):401-21 [9930576.001]
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):181-8 [10737722.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1742-9 [10749148.001]
  • [Cites] Cancer Gene Ther. 2000 Mar;7(3):422-9 [10766348.001]
  • [Cites] Mol Med. 1998 Jun;4(6):365-72 [10780879.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:51-4 [10804092.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):25-31 [10810459.001]
  • [Cites] Cancer Gene Ther. 2000 Apr;7(4):574-80 [10811475.001]
  • [Cites] Cancer Treat Rev. 2000 Jun;26(3):191-204 [10814561.001]
  • [Cites] Cancer Lett. 2000 Jul 3;155(1):71-7 [10814882.001]
  • [Cites] Cancer Gene Ther. 2000 May;7(5):789-98 [10830726.001]
  • [Cites] Hum Pathol. 2000 May;31(5):532-8 [10836292.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5019-31 [10866659.001]
  • [Cites] Anticancer Drug Des. 2000 Feb;15(1):67-72 [10888037.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 20;85(2):152-7 [8418305.001]
  • [Cites] Nature. 1993 Jun 17;363(6430):640-4 [8510758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5752-6 [8516324.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):472-6 [8595161.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):26-31 [2294702.001]
  • [Cites] Scand J Immunol. 1990 Jan;31(1):1-13 [2405475.001]
  • [Cites] Nature. 1989 Oct 12;341(6242):544-6 [2677748.001]
  • [Cites] Nature. 1989 Nov 2;342(6245):99-100 [2682259.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4597-603 [3396011.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1157-64 [7528107.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):986-91 [7547254.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1049-54 [7566963.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2419-25 [11001893.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Dec;78(2):165-71 [7828148.001]
  • [Cites] Cell. 1995 Jan 27;80(2):225-36 [7834742.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2445-52 [8628312.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1245-51 [8648380.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4164-70 [8797587.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4614-9 [8840973.001]
  • [Cites] Hum Gene Ther. 1996 Aug 1;7(12):1465-82 [8844206.001]
  • [Cites] Science. 1996 Nov 1;274(5288):784-7 [8864119.001]
  • (PMID = 18521343.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395489
  •  go-up   go-down






Advertisement